Abbott's Re-Acceleration: From Nutrition Recovery to CGM Reimbursement Upside

Inflection Point in the Portfolio

Abbott Laboratories’ second-quarter 2026 results were a clear step-up from the prior two quarters. Sales grew 4.8% on a comparable basis, and adjusted EPS of $1.31 beat the midpoint of guidance. Management reaffirmed the full-year comparable sales growth guide of 6.5–7.5% and raised EPS guidance to $5.45–$5.60, citing "momentum building across the portfolio." “Today, we issued second quarter results that included sales growth of 4.8% which represents an acceleration compared to the previous 2 quarters.” — Robert Ford, Chairman and Chief Executive Officer · 2026-07-16 The company is signaling that the difficult period of nutrition destocking and diagnostics headwinds is now behind it, and that the second half will be driven by four specific areas: Nutrition, Electrophysiology (EP), Core Lab, and Cancer Diagnostics.

Key Drivers: From Care Gap to Reimbursement Expansion

Perhaps the most striking theme on the call was the emphasis on reimbursement expansion as a catalyst for the CGM business. Robert Ford outlined that the U.S. type 2 non-insulin coverage could unlock "around 10 million Medicare beneficiaries," and that this could be a multi-billion dollar opportunity. He noted the company is "planning and positioning ourselves to be in the best possible position as it relates to Salesforce, distribution, etcetera." “But we are also planning and positioning ourselves to be in the best possible position as it relates to Salesforce, distribution, etcetera. To be able to capitalize on that opportunity.” — Robert Ford, Chairman and Chief Executive Officer · 2026-07-16 This is a clear departure from the previous calls where the company was more guarded about timing; now it is openly preparing for a broad launch.

On the diagnostics side, the integration of Exact Sciences is paying dividends. Cologuard growth was mid-teens, and the company highlighted the increasing role of care gap programs, which help health systems achieve HEDIS and star ratings. The management expects care gap volumes to ramp in the second half. “In May, the American Cancer Society updated its colorectal cancer screening guidelines reaffirming Cologuard and Cologuard Plus as preferred screening options.” — Robert Ford, Chairman and Chief Executive Officer · 2026-07-16 This validates the company's strategy to expand in Cancer Diagnostics, and the addition of a blood-based test could further broaden the market.

Contrasting with Market Fears

There is a notable contrast between investor anxiety about decelerating procedure volumes (as some hospital preannouncements suggest) and Abbott's own data. On the call, management pushed back firmly, citing its diagnostic instrument data. “I would argue that our US cardio business is performing better than it is ever been. And we are seeing that same similar strong stable demand internationally.” — Robert Ford, Chairman and Chief Executive Officer · 2026-07-16 The company sees its US core lab business growing 7.5% and hospital labs specifically up 13%, which is hardly a sign of weakness.

This divergence is important. Abbott is not discounting the macro concern, but its diverse portfolio provides a read-through across the healthcare system. The Mapping System and EP franchise also continue to gain traction, with the launch of Bolt PFA catheter and Tactiflex Duo, which should drive above-market growth in the back half.

Fundamental Backdrop

Even on the most recent filed quarter (Q1 2026, period ended March 31), the company's revenue trend remains solid. Total Revenue is consistently above $10B, and the long-term trend is upward. Management's confidence in margin expansion (they highlighted a 100bp gross margin improvement in Q2) suggests that the EPS raise is not purely a top-line story.

Importantly, the company is now looking ahead to 2027 and beyond, with a pipeline including balloon-expandable TAVR, leadless pacing, and a peripheral IVL. In the prior quarter (April 2026), Robert Ford reiterated his long-term bullishness on CGM: “I am very bullish on the CGM market-I always have been and I continue to be.” — Robert Ford, Chairman and Chief Executive Officer · 2026-04-16 And in January 2026, he described the nutrition pricing actions as "price promotion initiatives that are going to help invigorate growth" “we began implementing price promotion initiatives that are going to help invigorate growth.” — Robert Ford, Chairman and Chief Executive Officer · 2026-01-22 These have clearly taken hold, with nutritional sales improving sequentially.

What Changed, and Why It Matters

The most significant change this quarter is the shift from defensive management to attack mode. The company is now explicitly guiding to an acceleration, has identified the drivers, and is making strategic investments (e.g., a fifth CGM manufacturing facility) ahead of anticipated reimbursement changes. The

But the lift in the second half 80% of that lift, I am gonna call trajectory shift, really coming from 4 areas. Nutrition, electrophysiology core lab, and cancer diagnostics

This is a company that has been through a rough patch but now sees multiple engines firing. The combination of a recovering nutrition business, a step-up in EP growth from new products, a stabilizing core lab with the China VBP headwind fading, and the high-growth Exact Sciences integration makes the 7% growth target look credible. Moreover, the optionality from CGM reimbursement expansion is a potential upside that is not baked into guidance.

For investors, the key takeaway is that Abbott is back on offense. The stock has rallied over the past 90 days (up ~16%), and the tone of the call suggests that management believes the worst is over. With a strong pipeline and a clear strategy, Abbott appears well positioned to reassert its historical pattern of high single-digit top-line and double-digit bottom-line growth.